Moss Eloise, McEachern Jasmine, Adye-White Lauren, Priest Kelsey C, Gorfinkel Lauren, Wood Evan, Cullen Walter, Klimas Jan
Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, CANADA, V6Z 1Y6.
British Columbia Centres on Substance Use and Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, CANADA, V6Z 1Y6.
Can J Addict. 2018 Jun;9(2):6-9. doi: 10.1097/CXA.0000000000000015.
Urine drug screening (UDS) is commonly used to detect or validate self-reported substance use, particularly when beginning and maintaining opioid agonist therapy (OAT). However, there is currently no summary of the published clinical practice guidelines for UDS in Canada, and no measure of the consistency with which different provinces suggest administering UDS. Therefore, we conducted a policy scan of UDS guidelines, examining the published clinical practice guidelines for each Canadian province and extracting all relevant data in March 2017. Our Canadian guideline and policy scan found that UDS frequency recommendations vary greatly among Provinces for persons receiving OAT for opioid use disorder.
尿液药物筛查（UDS）通常用于检测或验证自我报告的药物使用情况，尤其是在开始和维持阿片类激动剂治疗（OAT）时。然而，目前加拿大尚无已发表的UDS临床实践指南总结，也没有衡量不同省份建议进行UDS的一致性程度的指标。因此，我们对UDS指南进行了政策审查，研究了加拿大每个省份已发表的临床实践指南，并于2017年3月提取了所有相关数据。我们对加拿大指南和政策的审查发现，对于接受阿片类药物使用障碍OAT治疗的患者，各省关于UDS频率的建议差异很大。
